Form 4: SGMO Officer Sells Shares for Tax Withholding

Sangamo Therapeutics' Principal Financial Officer, Prathyusha Duraibabu, disposed of 2,544 common shares for mandatory tax withholding following an RSU vesting event.

Summary

• Prathyusha Duraibabu, Principal Financial Officer of Sangamo Therapeutics, Inc. (SGMO), reported a disposition of 2,544 shares of common stock.
• The transaction occurred on November 24, 2025, at a price of $0.4166 per share.
• This disposition was solely for mandatory tax withholding purposes related to the vesting of a restricted stock unit (RSU) grant.
• The transaction is not a discretionary trade by the reporting person.
• Following this transaction, Prathyusha Duraibabu beneficially owns 696,718 shares of common stock.

Sentiment

Score: 5

Explanation: The transaction is a neutral, routine event for tax withholding related to RSU vesting, with no discretionary trading implications.

Positives

• The transaction is a routine tax withholding event, indicating the vesting of previously granted restricted stock units, which is a form of compensation.
• The officer retains a significant beneficial ownership of 696,718 shares, demonstrating continued alignment with shareholder interests.

Negatives

• The disposition of shares, even for tax purposes, reduces the officer's direct shareholding.

Future Outlook

The filing details future vesting schedules for the Principal Financial Officer's restricted stock units, with installments extending through February 2026 and beyond, contingent on continuous service.

Industry Context

This is a routine insider transaction related to executive compensation, common across all industries for publicly traded companies where equity awards are part of compensation packages. It does not reflect specific industry trends or competitive positioning.

Comparison to Industry Standards

• The practice of surrendering shares for tax withholding upon RSU vesting is a standard mechanism for managing equity compensation and is widely adopted by companies across various sectors, including biotechnology and pharmaceuticals, to comply with tax obligations for employees receiving equity awards.
• No specific comparable companies or projects are mentioned in the filing to allow for a direct comparison of results.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine tax-related transaction, not a discretionary sale indicating a change in confidence. The officer retains substantial equity.
• Employees: Reinforces the company's equity compensation structure and the vesting process for RSUs.

Next Steps

• Remaining 5,010 shares from the February 24, 2023 RSU grant will vest on February 24, 2026.
• 89,063 shares from the January 22, 2024 RSU grant will vest in successive equal quarterly installments through January 22, 2026.
• 120,000 shares from the February 25, 2025 RSU grant will vest as to one-fourth on February 25, 2026, with the remainder vesting in 8 successive equal quarterly installments thereafter.

Key Dates

Recommendation

This Form 4 filing reports a routine, non-discretionary sale of shares by a Principal Financial Officer for mandatory tax withholding upon RSU vesting. Such transactions are common and do not typically signal a change in management's outlook or the company's fundamentals. The officer retains a significant beneficial ownership, suggesting continued alignment. Therefore, based solely on this filing, a 'hold' recommendation is appropriate as it provides no new information to alter an existing investment thesis.

Keywords

Sangamo Therapeutics, SGMO, Form 4, Insider Transaction, Restricted Stock Units, RSU, Tax Withholding, Officer Stock Sale, Prathyusha Duraibabu, Equity Incentive Plan